FTX 001
Alternative Names: FLM-7523; FTX-001; MALAT1 antisense oligonucleotide; MALAT1 RNA-targeted therapy - Flamingo TherapeuticsLatest Information Update: 15 Jun 2023
At a glance
- Originator Ionis Pharmaceuticals
- Developer Flamingo Therapeutics
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action MALT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Solid tumours
Most Recent Events
- 14 Apr 2023 Adverse events and pharmacodynamics data from preclinical studies in Breast cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 02 Mar 2023 Flamingo Therapeutics and Dynacure sign merger agreement to combine their pipelines
- 02 Mar 2023 Flamingo Therapeutics plans to submit IND application for FTX 001 in Solid tumours